Related Articles by Review for PMID: 35593797

Year	Number of Results
2016	1
2017	1
2018	2
2019	2
2020	4
2021	6
2022	8
2023	11
2024	13
2025	1

1

Padda IS, Mahtani AU, Patel P, Parmar M. Padda IS, et al. 2024 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 35593797 Free Books & Documents.

2

RNA interference therapy in cardiology: will new targets improve therapeutic goals?

Fazoli RT, Drager LF, Kalil-Filho R, Generoso G. Fazoli RT, et al. Drugs Context. 2024 Aug 20;13:2024-3-1. doi: 10.7573/dic.2024-3-1. eCollection 2024. Drugs Context. 2024. PMID: 39188988 Free PMC article. Review.

3

Inclisiran: A Review in Hypercholesterolemia.

Frampton JE. Frampton JE. Am J Cardiovasc Drugs. 2023 Mar;23(2):219-230. doi: 10.1007/s40256-023-00568-7. Epub 2023 Mar 4. Am J Cardiovasc Drugs. 2023. PMID: 36869996 Review.

4

The Growing Class of Novel RNAi Therapeutics.

Traber GM, Yu AM. Traber GM, et al. Mol Pharmacol. 2024 Jun 18;106(1):13-20. doi: 10.1124/molpharm.124.000895. Mol Pharmacol. 2024. PMID: 38719476 Free PMC article. Review.

5

The growth of siRNA-based therapeutics: Updated clinical studies.

Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB. Zhang MM, et al. Biochem Pharmacol. 2021 Jul;189:114432. doi: 10.1016/j.bcp.2021.114432. Epub 2021 Jan 26. Biochem Pharmacol. 2021. PMID: 33513339 Free PMC article. Review.

6

Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review.

Ranasinghe P, Addison ML, Dear JW, Webb DJ. Ranasinghe P, et al. Br J Pharmacol. 2023 Nov;180(21):2697-2720. doi: 10.1111/bph.15972. Epub 2022 Nov 13. Br J Pharmacol. 2023. PMID: 36250252 Free article. Review.

7

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).

Sinning D, Landmesser U. Sinning D, et al. Curr Cardiol Rep. 2020 Oct 21;22(12):176. doi: 10.1007/s11886-020-01427-6. Curr Cardiol Rep. 2020. PMID: 33089390 Free PMC article. Review.

8

Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.

Samuel E, Watford M, Egolum UO, Ombengi DN, Ling H, Cates DW. Samuel E, et al. Ann Pharmacother. 2023 Mar;57(3):317-324. doi: 10.1177/10600280221105169. Epub 2022 Jun 30. Ann Pharmacother. 2023. PMID: 35775133 Review.

9

Advances in structural-guided modifications of siRNA.

Li Q, Dong M, Chen P. Li Q, et al. Bioorg Med Chem. 2024 Aug 1;110:117825. doi: 10.1016/j.bmc.2024.117825. Epub 2024 Jun 28. Bioorg Med Chem. 2024. PMID: 38954918 Review.

10

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a).

Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Katsiki N, et al. Pharmaceuticals (Basel). 2023 Apr 12;16(4):577. doi: 10.3390/ph16040577. Pharmaceuticals (Basel). 2023. PMID: 37111334 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Related Articles by Review for PMID: 35593797

43 results

Results by year